Higher doses of naloxone increase the number of naloxone-bound brain receptors, lowering the number of brain receptors bound with an opioid, according to a study by Adamis Pharmaceuticals.
Naloxone binds to the opioid receptors in the brain and reverses toxicity. The drug is used to resuscitate an overdose victim. Higher doses are required to resuscitate a patient when synthetic opioids cause the opioid overdose.
Researchers gave monkeys the synthetic opioid carfentanil followed by different doses of naloxone. Carfentanil is 100 times more potent than fentanyl and 10,000 times stronger than morphine.
After receiving naloxone, the monkeys’ brains were observed using Positron Emission Tomography imaging. The higher the level of naloxone, the higher the receptor occupancy.
Adamis manufactures ZIMHI, a high-dose naloxone injection product.
“We are pleased to see these published study results support the use of a higher dose naloxone product, such as the one we are developing,” Dr. Dennis J. Carlo, Adamis president and CEO, said. “We believe our ZIMHI naloxone injection could fill a void that currently exists in treating overdoses that result from more potent synthetic opioids. In the midst of the present COVID-19 pandemic, the need for a higher dose naloxone product may be greater than ever before.”